Strata Critical Medical, Inc. SRTA
Medical/Nursing Services · IPO 2019 · data as of November 13, 2026
Strata Critical Medical, Inc. (SRTA) is a healthcare company listed in the US with a market value of about $492M. In the twelve months to September 30, 2026 it had revenue of $281M and net income of -$25M, a net margin of -8.8%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: a price to free cash flow of 610.6, a 5-year average ROIC of -13%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 84% below the current price.
About Strata Critical Medical
Strata Critical Medical is listed in the US and classified in medical/nursing services, IPO year 2019. Revenue went from $67M in 2021 to $197M in 2025, growth of about 30.9% a year. It was profitable in 2 of the last 7 years in our data. Its share count rose by 15% over three years (dilution for shareholders).
Score: 1.4 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Positive free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $281M | $197M | $147M | $225M | $146M | $67M | — | — |
| Net income | -$25M | $41M | -$27M | -$56M | -$27M | -$37M | -$21M | $2M |
| Free cash flow | $806000 | -$59M | -$33M | -$34M | -$38M | -$6M | — | — |
| EPS (diluted) | $-0.30 | $0.50 | $-0.35 | $-0.76 | $-0.38 | $0.01 | $-2.17 | $0.19 |
| Net margin | -8.8% | 21.0% | -18.6% | -24.9% | -18.7% | -55.0% | — | — |
| ROIC | — | -7.9% | -9.7% | -25.7% | -17.8% | -3.6% | -10.7% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 4 analysts is $9.62, 75% above the current price; targets range from $8.00 to $13.00; the consensus rating is “Strong buy”; expected EPS is $-0.16 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Strata Critical Medical stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 84% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Strata Critical Medical pay a dividend?
Not currently.
Is Strata Critical Medical a good stock to buy?
We do not give buy or sell advice. Strata Critical Medical scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.